CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net income (loss)	$ 1,200	$ (3,783)	$ (21,357)
Adjustments to reconcile net loss to net cash flows provided by (used in) operating activities:
Share-based compensation	4,060	8,405	8,426
Impairment of clinical trial assets		2,130	0
Depreciation	687	1,401	1,718
Non-cash lease expenses		658	610
Impairment of goodwill	535	535	0
Amortization of intangible assets	191	380	345
Bad debt expense	349	289	2,391
Amortization of deferred financing costs		245	229
Accretion of asset retirement obligation		43	46
Gain on fixed asset disposal		0	(15)
Increase (decrease) in cash resulting from changes in:
Accounts receivable		(6,170)	301
Inventory		(3,633)	(1,993)
Prepaid expenses		2,832	2,061
Other assets		226	(353)
Accounts payable		(130)	442
Accrued compensation		(345)	(6,316)
Accrued expenses		1,218	740
Other liabilities		(574)	(503)
Net cash flows provided by (used in) operating activities		3,727	(13,228)
Cash flows from investing activities:
Purchases of equipment		(932)	(498)
Patent application costs		(93)	(103)
Proceeds from sale of equipment		0	24
Net cash flows used in investing activities		(1,025)	(577)
Cash flows from financing activities:
Proceeds from exercise of stock options		20	437
Principal payments on finance lease		(20)	(22)
Stock repurchased for tax withholdings on vesting of restricted stock		0	(1,191)
Net cash flows used in financing activities		0	(776)
Net change in cash		2,702	(14,581)
Cash and cash equivalents, beginning of period		65,950	87,083
Cash and cash equivalents, end of period	$ 68,652	$ 68,652	$ 72,502